Pulmonary hypertension: diagnostic and therapeutic challenges
- PMID: 26316767
- PMCID: PMC4544628
- DOI: 10.2147/TCRM.S74881
Pulmonary hypertension: diagnostic and therapeutic challenges
Abstract
Pulmonary hypertension (PH) is a hemodynamic and pathophysiologic state that can be found in multiple conditions with associated symptoms of dyspnea, decreased exercise tolerance, and progression to right heart failure. The World Health Organization has classified PH into five groups. The first group is pulmonary arterial hypertension (PAH), which can be idiopathic, heritable, due to drugs and toxins, or associated with conditions such as connective tissue diseases, congenital heart disease, portal hypertension, and others. The development of PAH is believed to result from smooth muscle cells and endothelial dysfunction that impairs production of vasodilators, including nitric oxide and prostacyclin. The importance of distinguishing this group from the other groups of PH is that there are PAH-specific drugs that target the molecular pathways that are pathogenic in the vascular derangements, leading to arterial hypertension, which should not be used in the other forms of PH. Other groups of PH include PH due to left heart disease, lung disease, chronic thromboembolic disease, as well as a miscellaneous category. Echocardiography is used to screen for PH and has varying sensitivity and specificity in detecting PH. Additionally, the right heart pressures estimated during echocardiogram often differ from those obtained during confirmatory testing with right heart catheterization. The most challenging PH diagnosis is in a case that does not fit one group of PH, but meets criteria that overlap between several groups. This also makes the treatment challenging because each group of PH is managed differently. This review provides an overview of the five groups of PH and discusses the diagnostic and therapeutic challenges of each.
Keywords: diagnosis; management; pulmonary arterial hypertension; pulmonary hypertension; right heart failure.
Figures

Similar articles
-
[Pulmonary arterial hypertension. Part I: pathobiologic, pathophysiologic, clinical and diagnostic aspects].G Ital Cardiol (Rome). 2009 May;10(5):271-300. G Ital Cardiol (Rome). 2009. PMID: 19537440 Review. Italian.
-
Pulmonary arterial hypertension: new insights into the optimal role of current and emerging prostacyclin therapies.Am J Cardiol. 2013 Mar 4;111(5 Suppl):1A-16A; quiz 17A-19A. doi: 10.1016/j.amjcard.2012.12.002. Am J Cardiol. 2013. PMID: 23414683 Review.
-
[Investigation of pulmonary hypertension].Rev Pneumol Clin. 2008 Jun;64(3):151-61. doi: 10.1016/j.pneumo.2008.05.001. Epub 2008 Jul 7. Rev Pneumol Clin. 2008. PMID: 18656791 Review. French.
-
[Pulmonary arterial hypertension].Rev Prat. 2004 Jan 15;54(1):5-13. Rev Prat. 2004. PMID: 15049592 Review. French.
-
Pulmonary arterial hypertension in the setting of scleroderma is different than in the setting of lupus: A review.Respir Med. 2018 Jan;134:42-46. doi: 10.1016/j.rmed.2017.11.020. Epub 2017 Dec 2. Respir Med. 2018. PMID: 29413506 Review.
Cited by
-
Pulmonary Tumor Thrombotic Microangiopathy with Administration of Pulmonary Vasodilator Resulting in Clinical Improvement Prior to Final Diagnosis.Am J Case Rep. 2021 Oct 6;22:e933867. doi: 10.12659/AJCR.933867. Am J Case Rep. 2021. PMID: 34611123 Free PMC article.
-
Utility of Hepatocyte Growth Factor as a Biomarker for Early Diagnosis of Pulmonary Artery Hypertension.Mol Diagn Ther. 2016 Oct;20(5):463-8. doi: 10.1007/s40291-016-0214-3. Mol Diagn Ther. 2016. PMID: 27342109
-
Inactivated Pseudomonas aeruginosa inhibits hypoxia-induced pulmonary hypertension by preventing TGF-β1/Smad signaling.Braz J Med Biol Res. 2016 Aug 25;49(10):e5526. doi: 10.1590/1414-431X20165526. Braz J Med Biol Res. 2016. PMID: 27580007 Free PMC article.
-
Imbalanced prostanoid release mediates cigarette smoke-induced human pulmonary artery cell proliferation.Respir Res. 2022 May 28;23(1):136. doi: 10.1186/s12931-022-02056-z. Respir Res. 2022. PMID: 35643499 Free PMC article.
-
Comparison of the clinical phenotype of systemic sclerosis patients in Iran and France in two university centers.J Scleroderma Relat Disord. 2019 Jun;4(2):149-159. doi: 10.1177/2397198318809224. Epub 2018 Nov 20. J Scleroderma Relat Disord. 2019. PMID: 35382390 Free PMC article.
References
-
- Simonneau G, Gatzoulis MA, Adatia I, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2013;62(25_S):D34–D41. - PubMed
-
- Mozaffarian D, Benjamin EJ, Go AS, et al. American Heart Association Statistics Committee and Stroke Statistics Subcommittee Heart disease and stroke statistics – 2015 update: a report from the American Heart Association. Circulation. 2015;131(4):e29–e322. - PubMed
-
- Humbert M, Morrell NW, Archer SL, et al. Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol. 2004;43(12 suppl):S13–S24. - PubMed
-
- Galiè N, Hoeper MM, Humbert M, et al. Task Force for Diagnosis and Treatment of Pulmonary Hypertension of European Society of Cardiology (ESC) European Respiratory Society (ERS) International Society of Heart and Lung Transplantation (ISHLT) Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J. 2009;34(6):1219–1263. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources